Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Market Closed 05-15 16:00:00 EDT

0.5200

-0.0086

-1.63%

盘后0.5201

+0.0001+0.02%

19:57 EDT

High0.5379	Low0.5200	Vol264.96K
Open0.5245	D1 Closing0.5286	Amplitude3.39%
Mkt Cap5.30M	Tradable Cap5.27M	Total Shares10.19M
T/O139.85K	T/O Rate2.61%	Tradable Shares10.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":0.52,"timestamp":1778875200000,"preClose":0.5286,"halted":0,"volume":264957,"hourTrading":{"tag":"盘后","latestPrice":0.5201,"preClose":0.52,"latestTime":"19:57 EDT","volume":9113,"amount":4840.7517,"timestamp":1778889458970,"change":0.0001,"changeRate":0.000192,"amplitude":0.027692},"delay":0,"changeRate":-0.016269390843738067,"floatShares":10143900,"shares":10190300,"eps":-24.12,"marketStatus":"Market Closed","change":-0.0086,"latestTime":"05-15 16:00:00 EDT","open":0.5245,"high":0.537899,"low":0.52,"amount":139845.27434262,"amplitude":0.033861,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-24.12,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":0.5286,"preHourTrading":{"tag":"盘前","latestPrice":0.5203,"preClose":0.5286,"latestTime":"09:27 EDT","volume":19767,"amount":10661.60897868,"timestamp":1778851654643,"change":-0.0083,"changeRate":-0.015702,"amplitude":0.070185},"postHourTrading":{"tag":"盘后","latestPrice":0.5201,"preClose":0.52,"latestTime":"19:57 EDT","volume":9113,"amount":4840.7517,"timestamp":1778889458970,"change":0.0001,"changeRate":0.000192,"amplitude":0.027692},"volumeRatio":0.7794493927182049},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"2635508287","title":"Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635508287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635508287?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:35","pubTimestamp":1778848500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA5XVLN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211921","title":"Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211921","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211921?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:41","pubTimestamp":1778589679,"startTime":"0","endTime":"0","summary":"Clearmind Medicine dosed two more patients in fourth cohort of its FDA-cleared Phase I/IIa trial of CMND-100 for moderate to severe alcohol use disorder, lifting total treated to 20.Results have not been presented; trial remains ongoing, with safety, tolerability, drug exposure, and early signs of benefit still being evaluated.So far, study has shown encouraging safety and tolerability, with no serious adverse events reported in first three cohorts.Fourth cohort moved to a higher dose following a positive independent safety review, supporting continued dose escalation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL9t8GL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4588","LU2210149790.SGD","BK4007","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","CMND","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4585","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634607211","title":"Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2634607211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634607211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:41","pubTimestamp":1778589660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUABQLD0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211781","title":"Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211781?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:41","pubTimestamp":1778589660,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, May  12, 2026  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292863/0/en/Clearmind-Medicine-Reaches-Important-Clinical-Milestone-20-Participants-Now-Treated-in-Ongoing-Phase-I-IIa-Trial-of-CMND-100-for-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634378286","title":"Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2634378286","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634378286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:55","pubTimestamp":1778500516,"startTime":"0","endTime":"0","summary":"Clearmind Medicine will host live webinar “Inside MEAI: New Insights from CMND-100 Psychedelic Clinical Trial” on June 10, 2026, 4:00 PM–5:00 PM IDT.Session set to review latest clinical data from ongoing FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder.Webinar scheduled to include presentations from trial investigators at Yale School of Medicine, Johns Hopkins Medicine, followed by live Q&A.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLc1HtpQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","CMND","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634323286","title":"Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634323286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634323286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:55","pubTimestamp":1778500500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA4JXRCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943966","title":"BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943966","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943966?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:53","pubTimestamp":1777985586,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of PtsdMay 5 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ANN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nFWN41I167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943647","title":"Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of Ptsd","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943647?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:50","pubTimestamp":1777985451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nFWN41I167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632610196","title":"Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2632610196","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632610196?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:02","pubTimestamp":1777582943,"startTime":"0","endTime":"0","summary":"Clearmind Medicine said board chair Amitay Weiss resigned effective immediately on April 26, 2026.Directors appointed Asaf Itzhaik to compensation committee plus nominating and corporate governance committee.Audit committee chair role shifted to Itzhaik, with Kiron-Revach plus Yehonatan Shachar also serving.Board classified Kiron-Revach, Shachar plus Itzhaik as independent directors under Nasdaq listing standards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL7vwrM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630128395","title":"Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630128395","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630128395?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:43","pubTimestamp":1777290207,"startTime":"0","endTime":"0","summary":"Clearmind Medicine began evaluating lead candidate CMND-100  for potential FDA Breakthrough Therapy Designation for Alcohol Use Disorder.Positive clinical results have already been presented from its ongoing FDA-approved Phase I/IIa trial, supporting eligibility assessment.Program targets a non-hallucinogenic treatment approach, positioning CMND-100 as a potential new option in a market with limited effective therapies.No Breakthrough Therapy Designation request has been submitted for MEAI, with no FDA designation granted as of April 27, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL3LhkPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4007","BK4588","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","CMND","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395135","title":"Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395135?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:41","pubTimestamp":1777290060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA1WN8P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779252","title":"Clearmind Medicine issues $2.7 million convertible notes at 10% discount","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779252","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629779252?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:18","pubTimestamp":1776719923,"startTime":"0","endTime":"0","summary":"Clearmind Medicine entered agreement on April 20, 2026 to sell convertible promissory notes with aggregate principal amount of USD 2.7 million.Cash purchase price set at 90% of principal, or USD 2.43 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL7ggxL7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629756227","title":"Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629756227","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629756227?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:03","pubTimestamp":1776715424,"startTime":"0","endTime":"0","summary":"Clearmind welcomed President Donald Trump’s April 18, 2026 executive order directing FDA to prioritize reviews for certain breakthrough-designated psychedelic therapies.Executive order also expands patient access pathways, which Clearmind framed as a catalyst for veteran mental health care.Clearmind highlighted February 2026 bipartisan House bill H.R. 7091 as a milestone that explicitly named its MEAI compound for potential VA-supported trials.Company said it is advancing FDA-authorized Phase I/IIa trials of lead candidate CMND-100 for alcohol use disorder at Yale School of Medicine and Johns Hopkins University.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLTf5rZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","CMND","SG9999014021.USD","SG9999014005.SGD","BK4588","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4007","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628265087","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2628265087","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628265087?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:34","pubTimestamp":1776692072,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nAQN2LVC04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628422427","title":"Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628422427","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628422427?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683722,"startTime":"0","endTime":"0","summary":"Clearmind Medicine reported positive top-line safety results from its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on April 20, 2026.Data from third cohort showed drug candidate was well tolerated at highest dose tested so far, with no serious adverse events reported.Study met its primary endpoint on safety and tolerability, supporting continued development of CMND-100 as a potential non-hallucinogenic oral treatment option for Alcohol Use Disorder.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL6T4625:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND","BK4588","NDAQ","IE00BN0W2W23.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628219742","title":"Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2628219742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628219742?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130GP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628427957","title":"Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628427957","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628427957?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:15","pubTimestamp":1776683700,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April  20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276876/0/en/Clearmind-Medicine-Announced-Positive-Top-Line-Safety-Results-CMND-100-Proprietary-Psychedelic-Treatment-Meets-Primary-Endpoint-in-AUD-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627212996","title":"Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627212996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627212996?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:27","pubTimestamp":1776353261,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a primary endpoint achievement, a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearminds-cmnd-100-meets-primary-endpoint-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearminds-cmnd-100-meets-primary-endpoint-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627721292","title":"Clearmind announces DSMB recommendation to continue CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627721292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627721292?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:26","pubTimestamp":1776353212,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced Wednesday that its independent Data and Safety Monitoring Board has completed its review and issued a positive ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-announces-dsmb-recommendation-to-continue-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-announces-dsmb-recommendation-to-continue-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627879032","title":"Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2627879032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627879032?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:16","pubTimestamp":1776259005,"startTime":"0","endTime":"0","summary":"Clearmind received a positive recommendation from an independent Data and Safety Monitoring Board to continue its FDA-approved Phase I/IIa trial of CMND-100 in patients with moderate to severe Alcohol Use Disorder.Top-line safety results have already been presented internally to the board, showing CMND-100 was well tolerated with no serious adverse events reported.Clearmind will advance to fourth cohort, raising tested dose to 160 mg.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7fBpnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.0559},{"period":"1month","weight":-0.2},{"period":"3month","weight":-0.5357},{"period":"6month","weight":-0.9544},{"period":"1year","weight":-0.9866},{"period":"ytd","weight":-0.7127}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.080284},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}